Clinical Trial Update: A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated the efficacy and safety of CGB-500, a 1% topical tofacitinib, versus an active comparator for atopic dermatitis. The study has complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• CGB-500 (tofacitinib)

Snippet

Sponsor: CAGE Bio Inc. | Conditions: Atopic Dermatitis (AD) | Phase 2 | Status: COMPLETED